JP2022512847A - 操作されたdnaポリメラーゼバリアント - Google Patents
操作されたdnaポリメラーゼバリアント Download PDFInfo
- Publication number
- JP2022512847A JP2022512847A JP2021523258A JP2021523258A JP2022512847A JP 2022512847 A JP2022512847 A JP 2022512847A JP 2021523258 A JP2021523258 A JP 2021523258A JP 2021523258 A JP2021523258 A JP 2021523258A JP 2022512847 A JP2022512847 A JP 2022512847A
- Authority
- JP
- Japan
- Prior art keywords
- dna polymerase
- amino acid
- substitution
- seq
- engineered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 title claims abstract description 286
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 title claims abstract description 283
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 195
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 190
- 229920001184 polypeptide Polymers 0.000 claims abstract description 189
- 239000002157 polynucleotide Substances 0.000 claims abstract description 92
- 238000000034 method Methods 0.000 claims abstract description 91
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 91
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 91
- 239000000203 mixture Substances 0.000 claims abstract description 31
- 238000006467 substitution reaction Methods 0.000 claims description 167
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 107
- 108090000623 proteins and genes Proteins 0.000 claims description 63
- 238000003752 polymerase chain reaction Methods 0.000 claims description 54
- 230000000694 effects Effects 0.000 claims description 34
- 239000012634 fragment Substances 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 30
- 239000013612 plasmid Substances 0.000 claims description 25
- 230000003321 amplification Effects 0.000 claims description 22
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 22
- 239000013604 expression vector Substances 0.000 claims description 20
- 230000001976 improved effect Effects 0.000 claims description 20
- 108091093088 Amplicon Proteins 0.000 claims description 16
- 230000035772 mutation Effects 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 108010006785 Taq Polymerase Proteins 0.000 claims description 11
- 241001495444 Thermococcus sp. Species 0.000 claims description 11
- 108010002747 Pfu DNA polymerase Proteins 0.000 claims description 10
- 241000205156 Pyrococcus furiosus Species 0.000 claims description 10
- 241000589500 Thermus aquaticus Species 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 102000003960 Ligases Human genes 0.000 claims description 7
- 108090000364 Ligases Proteins 0.000 claims description 7
- 230000006872 improvement Effects 0.000 claims description 7
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 6
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 6
- 239000005090 green fluorescent protein Substances 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 5
- 230000009466 transformation Effects 0.000 claims description 5
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 claims description 4
- 238000012203 high throughput assay Methods 0.000 claims description 3
- 238000007363 ring formation reaction Methods 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 description 129
- 210000004027 cell Anatomy 0.000 description 114
- 102000053602 DNA Human genes 0.000 description 83
- 108020004414 DNA Proteins 0.000 description 83
- 229940024606 amino acid Drugs 0.000 description 72
- 150000001413 amino acids Chemical class 0.000 description 70
- 150000007523 nucleic acids Chemical class 0.000 description 53
- 102000004190 Enzymes Human genes 0.000 description 50
- 108090000790 Enzymes Proteins 0.000 description 50
- 229940088598 enzyme Drugs 0.000 description 50
- 238000006243 chemical reaction Methods 0.000 description 35
- 230000014509 gene expression Effects 0.000 description 35
- 102000039446 nucleic acids Human genes 0.000 description 32
- 108020004707 nucleic acids Proteins 0.000 description 32
- 239000000523 sample Substances 0.000 description 27
- 239000000047 product Substances 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 25
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 24
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 24
- 125000000539 amino acid group Chemical group 0.000 description 23
- 108091026890 Coding region Proteins 0.000 description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 description 19
- 230000037430 deletion Effects 0.000 description 19
- 238000012217 deletion Methods 0.000 description 19
- 239000013598 vector Substances 0.000 description 18
- 108010076504 Protein Sorting Signals Proteins 0.000 description 15
- 239000000758 substrate Substances 0.000 description 15
- 241000894007 species Species 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- 238000009396 hybridization Methods 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 108020004705 Codon Proteins 0.000 description 12
- -1 and analogs Substances 0.000 description 12
- 230000037431 insertion Effects 0.000 description 12
- 238000003780 insertion Methods 0.000 description 12
- 230000001105 regulatory effect Effects 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 230000002255 enzymatic effect Effects 0.000 description 10
- 230000010076 replication Effects 0.000 description 10
- 102000035195 Peptidases Human genes 0.000 description 9
- 108091005804 Peptidases Proteins 0.000 description 9
- 239000006166 lysate Substances 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 238000002703 mutagenesis Methods 0.000 description 9
- 231100000350 mutagenesis Toxicity 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000007481 next generation sequencing Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 108010065511 Amylases Proteins 0.000 description 7
- 102000013142 Amylases Human genes 0.000 description 7
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 7
- 240000006439 Aspergillus oryzae Species 0.000 description 7
- 102000012410 DNA Ligases Human genes 0.000 description 7
- 108010061982 DNA Ligases Proteins 0.000 description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 108020004511 Recombinant DNA Proteins 0.000 description 7
- 235000019418 amylase Nutrition 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 230000010354 integration Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000228245 Aspergillus niger Species 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 238000000137 annealing Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 230000002538 fungal effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- 239000004382 Amylase Substances 0.000 description 5
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 5
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 108090000637 alpha-Amylases Proteins 0.000 description 5
- 102000004139 alpha-Amylases Human genes 0.000 description 5
- 229940024171 alpha-amylase Drugs 0.000 description 5
- 235000003704 aspartic acid Nutrition 0.000 description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
- 229960005091 chloramphenicol Drugs 0.000 description 5
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 230000008488 polyadenylation Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 229920002477 rna polymer Polymers 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 241000228212 Aspergillus Species 0.000 description 4
- 101000757144 Aspergillus niger Glucoamylase Proteins 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 4
- 241000206602 Eukaryota Species 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 241000235402 Rhizomucor Species 0.000 description 4
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 4
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229960003767 alanine Drugs 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 239000005547 deoxyribonucleotide Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 108091006047 fluorescent proteins Proteins 0.000 description 4
- 102000034287 fluorescent proteins Human genes 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000019833 protease Nutrition 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 239000001226 triphosphate Substances 0.000 description 4
- 235000011178 triphosphate Nutrition 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- 229960004295 valine Drugs 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 241000351920 Aspergillus nidulans Species 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 101000695691 Bacillus licheniformis Beta-lactamase Proteins 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000005549 deoxyribonucleoside Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 108010029675 Bacillus licheniformis alpha-amylase Proteins 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000223221 Fusarium oxysporum Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 101150076840 PolI gene Proteins 0.000 description 2
- 102000000823 Polynucleotide Ligases Human genes 0.000 description 2
- 108010001797 Polynucleotide Ligases Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 241000191043 Rhodobacter sphaeroides Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 102220609894 Vasoactive intestinal polypeptide receptor 1_D55K_mutation Human genes 0.000 description 2
- 108010048241 acetamidase Proteins 0.000 description 2
- 108020002494 acetyltransferase Proteins 0.000 description 2
- 102000005421 acetyltransferase Human genes 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229940025131 amylases Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 238000012219 cassette mutagenesis Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 101150109249 lacI gene Proteins 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002342 ribonucleoside Substances 0.000 description 2
- 101150098466 rpsL gene Proteins 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 description 1
- 101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 108020000992 Ancient DNA Proteins 0.000 description 1
- 241000534414 Anotopterus nikparini Species 0.000 description 1
- 108010037870 Anthranilate Synthase Proteins 0.000 description 1
- 101150018431 Arx gene Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101000690713 Aspergillus niger Alpha-glucosidase Proteins 0.000 description 1
- 101900127796 Aspergillus oryzae Glucoamylase Proteins 0.000 description 1
- 101900318521 Aspergillus oryzae Triosephosphate isomerase Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108700010154 BRCA2 Genes Proteins 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100030981 Beta-alanine-activating enzyme Human genes 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000000496 Carboxypeptidases A Human genes 0.000 description 1
- 108010080937 Carboxypeptidases A Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010071146 DNA Polymerase III Proteins 0.000 description 1
- 102000007528 DNA Polymerase III Human genes 0.000 description 1
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 1
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 1
- 101710159156 DNA polymerase IV Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 101100342470 Dictyostelium discoideum pkbA gene Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 102000004860 Dipeptidases Human genes 0.000 description 1
- 108090001081 Dipeptidases Proteins 0.000 description 1
- 241000006271 Discosoma sp. Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 101000939283 Escherichia coli (strain K12) Protein UmuC Proteins 0.000 description 1
- 101000939288 Escherichia coli (strain K12) Protein UmuD Proteins 0.000 description 1
- 101100385973 Escherichia coli (strain K12) cycA gene Proteins 0.000 description 1
- 241001137858 Euryarchaeota Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 101150108358 GLAA gene Proteins 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- 101100080316 Geobacillus stearothermophilus nprT gene Proteins 0.000 description 1
- 241001272178 Glires Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- 101100295959 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) arcB gene Proteins 0.000 description 1
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 1
- 102220576709 Hemoglobin subunit mu_D15G_mutation Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- 101000773364 Homo sapiens Beta-alanine-activating enzyme Proteins 0.000 description 1
- 102220475732 Immunoglobulin kappa variable 2-24_I13T_mutation Human genes 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 101150068888 MET3 gene Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 101100022915 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-11 gene Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 1
- 101710113020 Ornithine transcarbamylase, mitochondrial Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 201000010273 Porphyria Cutanea Tarda Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101900232935 Pyrococcus furiosus DNA polymerase Proteins 0.000 description 1
- 101710086015 RNA ligase Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 101100022918 Schizosaccharomyces pombe (strain 972 / ATCC 24843) sua1 gene Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101100309436 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) ftf gene Proteins 0.000 description 1
- 101100370749 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) trpC1 gene Proteins 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 101100157012 Thermoanaerobacterium saccharolyticum (strain DSM 8691 / JW/SL-YS485) xynB gene Proteins 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 240000001085 Trapa natans Species 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 101150050575 URA3 gene Proteins 0.000 description 1
- 102220479767 Vacuolar protein sorting-associated protein 35_K95R_mutation Human genes 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 108010045649 agarase Proteins 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000005427 anthranyl group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 101150009206 aprE gene Proteins 0.000 description 1
- 101150008194 argB gene Proteins 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 102220363900 c.182A>C Human genes 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 101150005799 dagA gene Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000007848 endpoint PCR Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108010021843 fluorescent protein 583 Proteins 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000002952 image-based readout Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 101150039489 lysZ gene Proteins 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 101150095344 niaD gene Proteins 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 108090000021 oryzin Proteins 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 101150019841 penP gene Proteins 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- NUSQOFAKCBLANB-UHFFFAOYSA-N phthalocyanine tetrasulfonic acid Chemical compound C12=CC(S(=O)(=O)O)=CC=C2C(N=C2NC(C3=CC=C(C=C32)S(O)(=O)=O)=N2)=NC1=NC([C]1C=CC(=CC1=1)S(O)(=O)=O)=NC=1N=C1[C]3C=CC(S(O)(=O)=O)=CC3=C2N1 NUSQOFAKCBLANB-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000037048 polymerization activity Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 101150108007 prs gene Proteins 0.000 description 1
- 101150086435 prs1 gene Proteins 0.000 description 1
- 101150070305 prsA gene Proteins 0.000 description 1
- 101150054232 pyrG gene Proteins 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 102200075063 rs104894696 Human genes 0.000 description 1
- 102220219331 rs1060501710 Human genes 0.000 description 1
- 102220279089 rs1554821020 Human genes 0.000 description 1
- 102220001330 rs267606642 Human genes 0.000 description 1
- 102220040213 rs587778234 Human genes 0.000 description 1
- 102220316041 rs786202335 Human genes 0.000 description 1
- 102200082234 rs786205157 Human genes 0.000 description 1
- 102220141943 rs886059088 Human genes 0.000 description 1
- 102220275598 rs996732250 Human genes 0.000 description 1
- 101150025220 sacB gene Proteins 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 101150016309 trpC gene Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 239000013026 undiluted sample Substances 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 101150110790 xylB gene Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07007—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/10—Nucleotidyl transfering
- C12Q2521/101—DNA polymerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/113—PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
- C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/91245—Nucleotidyltransferases (2.7.7)
- G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
- G01N2333/9126—DNA-directed DNA polymerase (2.7.7.7)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
配列表、表、またはコンピュータープログラムへの参照
略語および定義:
操作されたDNAポリメラーゼポリペプチド:
操作されたポリペプチドをコードするポリヌクレオチド、発現ベクター、および宿主細胞:
(実施例1)
DNAポリメラーゼ遺伝子取得および発現ベクターの構築
(実施例2)
ハイスループット(HTP)Pol3 DNAポリメラーゼの発現およびライセート調製
Pol3ポリメラーゼおよびバリアントのハイスループット成長
HTPペレットの溶解
(実施例3)
PCR産物収量アッセイ
ハイスループットポリメラーゼ忠実度試験
ポリメラーゼ忠実度の相対比較
複数のポリメラーゼ特性の同時スクリーニング
次世代シーケンシングにおけるカバレッジの均一性
Claims (47)
- 配列番号2、6、22、24、26、28、および/もしくは824の参照配列に対して少なくとも85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、もしくはそれを超える配列同一性を有するポリペプチド配列、またはその機能性断片を含む、操作されたDNAポリメラーゼであって、そのポリペプチド配列内に少なくとも1つの変異を含み、前記ポリペプチド配列のアミノ酸位置が、配列番号2、6、22、24、26、28、または824を参照して番号付けされている、操作されたDNAポリメラーゼ。
- 少なくとも1つの置換または置換セットが、21、21/66/247/282、247/282/575、282/575、283/647/702/743、339/647/661/664/668/702/712、372/391/702、391、391/647/659/661/668/671/712/716、391/647/659/661/668/671/716、391/647/659/664/668/702/728/732、391/647/659/664/671/702、391/647/661/664/671/702/716、391/647/671/728、391/659/702/716/732/737、391/661/664/668/671/716/737、391/671、391/702/712/716/732/743、647/659/661/664/668/702、647/659/664/668/702/712/737、647/659/668/671/716/728、647/668、647/668/671/712、659/702/743、661/664/668/671/716、668/702、671/702、671/702/716、702、および743、ならびに/またはこれらの任意の組合せから選択され、前記アミノ酸位置が、配列番号6を参照して番号付けされている、請求項1に記載の操作されたDNAポリメラーゼ。
- 少なくとも1つの置換または置換セットが、18/387、24/719、43/528、48/760、101/646、108/679、223、257、282、359、360、361、362、376/619、390、391、394、394/399、420、421、478、502、506、514、515、521、528、583/730、603、619、631、646、655、662、666、668、685、691、702、721、738、754、760、および761、ならびに/またはこれらの任意の組合せから選択されるアミノ酸位置における置換を含み、前記アミノ酸位置が、配列番号6を参照して番号付けされている、請求項1に記載の操作されたDNAポリメラーゼ。
- 少なくとも1つの置換または置換セットが、174/361/394/666/668/721、360/391、361/391/659、361/394/420/528/646/666/721/743、361/394/420/528/666、361/394/420/646/666/702/721/743、361/528/646/666、361/528/646/702/721、361/528/666、361/646、394/420、502/507/695、528/646/659/668/743、528/666、528/668、528/743、619、666、および685/691/743、ならびに/またはこれらの任意の組合せから選択されるアミノ酸位置における置換を含み、前記アミノ酸位置が、配列番号22を参照して番号付けされている、請求項1に記載の操作されたDNAポリメラーゼ。
- 少なくとも1つの置換または置換セットが、100、277、280、281、283、339、401、468、479、480、482、489、490、491、496、497、および498、ならびに/またはこれらの任意の組合せから選択されるアミノ酸位置における置換を含み、前記アミノ酸位置が、配列番号22を参照して番号付けされている、請求項1に記載の操作されたDNAポリメラーゼ。
- 少なくとも1つの置換または置換セットが、15/134/482/490/497/671/685、234/497/647、257/390/420、257/390/420/647、257/401/420、257/401/420/482/647/671/685、257/482/497/647、257/647、257/671/685/702、281、281/391/478、281/391/478/685、281/391/488/492、281/391/495/561/659/668、281/391/659/668、281/391/668、281/478/659/685/702、281/478/668、281/488、281/488/492/495/659/668、281/488/492/668/702、281/488/495、281/488/495/668、281/492/495/668、281/492/495/668/702、281/668、390/401/716、390/420、390/491/671、390/497、390/671/685、391、391/478、391/478/479/668、391/478/492/668、391/479/659/668、391/488/492/659/685、391/488/492/668、391/488/495/668/685/702、391/492/495、391/492/495/659、391/492/515/659/685、391/495/659、401、401/482/659/671/702、401/490、401/490/659/671、401/671、420、420/482/659/702、420/490、420/490/659/661/671、420/659/702、420/661/671、420/685、478、478/479、478/479/668、478/479/702、478/488/659、478/488/668/685/702、478/515、479/492、479/659/678、482/497/647/716、482/497/671/685、482/671/702/716、488、488/492、488/492/495、488/495、488/495/685、490/497/661/671/685/702/716、492、492/495/659/668、492/659/685、492/668/685/712、492/668/712、495、495/659、495/659/685、497/647、497/647/659/671、497/659/691/716、497/661、497/661/671、497/671/702、497/671/716、497/685、497/702、515、659、659/691、および671、ならびに/またはこれらの任意の組合せから選択されるアミノ酸位置における置換を含み、前記アミノ酸位置が、配列番号24を参照して番号付けされている、請求項1に記載の操作されたDNAポリメラーゼ。
- 少なくとも1つの置換または置換セットが、55/579、108、108/521、156/451、236/755、240、247、248、256、298、299、299/319、302、309、316、319、350、356、357、358、370、384、385、386、389、406、407、411、415、440、443、447、450、451、520、536、539、540、544、550/575、566、568、575、579、579/767、600、601、601/638、609/648、624、634、648、656、672、758、765、767、772、777、778、779、780、782、784、および785,ならびに/またはこれらの任意の組合せから選択されるアミノ酸位置における置換を含み、前記アミノ酸位置が、配列番号24を参照して番号付けされている、請求項1に記載の操作されたDNAポリメラーゼ。
- 少なくとも1つの置換または置換セットが、248、281、281/302、281/492、302/401、339/491/492/579/712、390/466/539/712、および661、ならびに/またはこれらの任意の組合せから選択されるアミノ酸位置における置換を含み、前記アミノ酸位置が、配列番号26を参照して番号付けされている、請求項1に記載の操作されたDNAポリメラーゼ。
- 少なくとも1つの置換または置換セットが、240/579、240/579/702、248/391/539/579/659/702、248/391/659、302/391/579、339/390/420/425/466/490/491/515/702、391、391/482、391/659、420/515、579、579/659/702、579/702、および659/702、ならびに/またはこれらの任意の組合せから選択されるアミノ酸位置における置換を含み、前記アミノ酸位置が、配列番号28を参照して番号付けされている、請求項1に記載の操作されたDNAポリメラーゼ。
- 少なくとも1つの置換または置換セットが、257、420、515、および521、ならびに/またはこれらの任意の組合せから選択されるアミノ酸位置における置換を含み、前記アミノ酸位置が、配列番号6を参照して番号付けされている、請求項1に記載の操作されたDNAポリメラーゼ。
- 少なくとも1つの置換または置換セットが、71/361/702/721/738、277、281、339、391/491、401、479、480、482、488、490、491、492、495、497、528/646/659/668/743、702/743、および743、ならびに/またはこれらの任意の組合せから選択されるアミノ酸位置における置換を含み、前記アミノ酸位置が、配列番号22を参照して番号付けされている、請求項1に記載の操作されたDNAポリメラーゼ。
- 少なくとも1つの置換または置換セットが、240、370、385、539、540、550/575、634、および777、ならびに/またはこれらの任意の組合せから選択されるアミノ酸位置における置換を含み、前記アミノ酸位置が、配列番号24を参照して番号付けされている、請求項1に記載の操作されたDNAポリメラーゼ。
- 少なくとも1つの置換または置換セットが、390/391、482、および515、ならびに/またはこれらの任意の組合せから選択されるアミノ酸位置における置換を含み、前記アミノ酸位置が、配列番号28を参照して番号付けされている、請求項1に記載の操作されたDNAポリメラーゼ。
- 少なくとも1つの置換または置換セットが、281、281/579、および/またはこれらの任意の組合せから選択されるアミノ酸位置における置換を含み、前記アミノ酸位置が、配列番号28を参照して番号付けされている、請求項1に記載の操作されたDNAポリメラーゼ。
- 少なくとも1つの置換または置換セットが、13、15、19、26、52、55、61、80、81、82、95、111、118、141、148、152、156、162、163、179、181、187、189、191、196、208、221、229、231、242、258、274、297、313、314、317、325、326、333、349、377、387、394、395、411、447、450、451、453、469、482、496、502、520、521、537、563、564、564/572、567、569、575、580、601、603、619、620、648、667、673、690、705、719、731、758、761、772、774、775、778、783、および784、ならびに/またはこれらの任意の組合せから選択されるアミノ酸位置における置換を含み、前記アミノ酸位置が、配列番号824を参照して番号付けされている、請求項1に記載の操作されたDNAポリメラーゼ。
- 少なくとも1つの置換または置換セットが、15/447/569/775/783/784、82/242/569、82/450/567/569、313、314/447/569/783/784、537/667、567/569/667、および569、ならびに/またはこれらの任意の組合せから選択されるアミノ酸位置における置換を含み、前記アミノ酸位置が、配列番号824を参照して番号付けされている、請求項1に記載の操作されたDNAポリメラーゼ。
- 表3.1、3.2、3.3,3.4、3.5、3.6、3.7、3.8、3.9、4.1、4.2、4.3、4.4、4.5、6.2、および/または6.3に記載される少なくとも1つの操作されたDNAポリメラーゼバリアントの配列に対して少なくとも85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、またはそれを超えて同一であるポリペプチド配列を含む、請求項1に記載の操作されたDNAポリメラーゼ。
- DNAポリメラーゼ活性を有する、請求項1から17のいずれかに記載の操作されたDNAポリメラーゼ。
- Pyrococcus furiosusに由来するPfu DNAポリメラーゼ、Thermococcus sp.株2319x1に由来するB群DNAポリメラーゼ、およびThermus aquaticusに由来するTaq DNAポリメラーゼから選択される野生型DNAポリメラーゼと比較して、少なくとも1つの改善された特性を有する、請求項1から18のいずれかに記載の操作されたDNAポリメラーゼ。
- 野生型DNAポリメラーゼと比較して、少なくとも1つの改善された特性を有し、前記改善された特性が、ポリメラーゼ連鎖反応において増加した産物を産生すること、より高い忠実度、およびより高い熱安定性から選択される、請求項19に記載の操作されたDNAポリメラーゼ。
- ポリメラーゼ連鎖反応において、野生型DNAポリメラーゼよりも高い産物収量をもたらし、前記野生型DNAポリメラーゼが、Pyrococcus furiosusに由来するPfu DNAポリメラーゼ、Thermococcus sp.株2319x1に由来するB群DNAポリメラーゼ、およびThermus aquaticusに由来するTaq DNAポリメラーゼから選択される、請求項1から20のいずれかに記載の操作されたDNAポリメラーゼ。
- 野生型DNAポリメラーゼよりも高い忠実度を呈し、前記野生型DNAポリメラーゼが、Pyrococcus furiosusに由来するPfu DNAポリメラーゼ、Thermococcus sp.株2319x1に由来するB群DNAポリメラーゼ、およびThermus aquaticusに由来するTaq DNAポリメラーゼから選択される、請求項1から21のいずれかに記載の操作されたDNAポリメラーゼ。
- 野生型DNAポリメラーゼよりも高い熱安定性を呈し、前記野生型DNAポリメラーゼが、Pyrococcus furiosusに由来するPfu DNAポリメラーゼ、Thermococcus sp.株2319x1に由来するB群DNAポリメラーゼ、およびThermus aquaticusに由来するTaq DNAポリメラーゼから選択される、請求項1から22のいずれかに記載の操作されたDNAポリメラーゼ。
- 前記ポリメラーゼが、精製されている、請求項1から23のいずれかに記載の操作されたDNAポリメラーゼ。
- 請求項1から24のいずれかに記載の少なくとも1つの操作されたDNAポリメラーゼをコードする、ポリヌクレオチド配列。
- 配列番号1、5、21、23、25、27、823の参照配列に対して少なくとも85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、またはそれを超える配列同一性を含む、ポリヌクレオチド配列、および/またはその機能性断片であって、操作されたポリペプチドが、1つまたは複数のアミノ酸位置における少なくとも1つの置換を含む、ポリヌクレオチド配列。
- 配列番号2、6、22、24、26、28、および/または824の参照配列に対して少なくとも85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、またはそれを超える配列同一性を有する配列を含む少なくとも1つの操作されたDNAポリメラーゼをコードする、請求項25および/または26に記載のポリヌクレオチド配列。
- 前記配列が、配列番号1、5、21、23、25、27、および/または823を含む、請求項27に記載のポリヌクレオチド配列。
- 制御配列に作動可能に連結されている、請求項25から28のいずれかに記載のポリヌクレオチド配列。
- コドン最適化されている、請求項25から29のいずれかに記載のポリヌクレオチド配列。
- 請求項25から30のいずれかに記載の少なくとも1つのポリヌクレオチド配列を含む、発現ベクター。
- 請求項31の少なくとも1つの発現ベクターで形質転換された、宿主細胞。
- 宿主細胞において操作されたDNAポリメラーゼポリペプチドを産生させる方法であって、請求項32に記載の宿主細胞を、少なくとも1つの操作されたDNAポリメラーゼが産生されるように、好適な培養条件下において培養することを含む、方法。
- 培養物および/または宿主細胞から、少なくとも1つの操作されたDNAポリメラーゼを回収することをさらに含む、請求項33に記載の方法。
- 前記少なくとも1つの操作されたDNAポリメラーゼを精製するステップをさらに含む、請求項34に記載の方法。
- 請求項1から24のいずれかに記載の少なくとも1つの操作されたDNAポリメラーゼを含む、組成物。
- DNAポリメラーゼの忠実度の決定のためのハイスループットアッセイ系。
- DNAポリメラーゼのハイスループット忠実度決定のための方法であって、i)請求項1から24のいずれかに記載の少なくとも1つのDNAポリメラーゼ、第1のレポータータンパク質および第2のレポータータンパク質および選択マーカーをコードする遺伝子を含むレポータープラスミド、ポリメラーゼ連鎖反応を行うためのサーモサイクラーおよび試薬を含む増幅系、および精製系、コンピテント宿主細胞を含む形質転換系、ならびにフローサイトメーターを提供することと、ii)前記DNAポリメラーゼおよび前記レポータープラスミドを、レポーター構築物が前記DNAポリメラーゼによって増幅されて、PCR産物を産生するような条件下において、前記増幅系に曝露することと、iii)前記PCR産物を環状化して、環状化PCRアンプリコンを得ることと、vi)前記形質転換系を使用して前記PCRアンプリコンを形質転換して、形質転換細胞を産生することと、vii)前記フローサイトメーターを使用して、前記形質転換細胞を分析することと、viii)前記DNAポリメラーゼの前記忠実度を決定することとを含む、方法。
- 前記形質転換細胞を誘導するステップをさらに含む、請求項38に記載の方法。
- 前記第1のレポータータンパク質が、緑色蛍光タンパク質を含む、請求項38および/または39に記載の方法。
- 前記第2のレポータータンパク質が、dsRedを含む、請求項38から40のいずれかに記載の方法。
- 前記選択マーカーが、クロラムフェニコールアセチルトランスフェラーゼを含む、請求項38から41のいずれかに記載の方法。
- 前記PCRアンプリコンの前記環状化が、少なくとも1つのリガーゼを使用して行われる、請求項38から42のいずれかに記載の方法。
- 前記PCRアンプリコンが、精製される、請求項38から43のいずれかに記載の方法。
- 参照DNAポリメラーゼと比較して、ポリメラーゼ忠実度における改善倍率を決定することをさらに含む、請求項38から44のいずれかに記載の方法。
- 前記参照DNAポリメラーゼが、野生型ポリメラーゼである、請求項45に記載の方法。
- 前記野生型ポリメラーゼが、Pyrococcus furiosusに由来するPfu DNAポリメラーゼ、Thermococcus sp.株2319x1に由来するB群DNAポリメラーゼ、およびThermus aquaticusに由来するTaq DNAポリメラーゼから選択される、請求項46に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2024025611A JP2024057009A (ja) | 2018-10-29 | 2024-02-22 | 操作されたdnaポリメラーゼバリアント |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862752215P | 2018-10-29 | 2018-10-29 | |
US62/752,215 | 2018-10-29 | ||
PCT/US2019/058310 WO2020092216A1 (en) | 2018-10-29 | 2019-10-28 | Engineered dna polymerase variants |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024025611A Division JP2024057009A (ja) | 2018-10-29 | 2024-02-22 | 操作されたdnaポリメラーゼバリアント |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022512847A true JP2022512847A (ja) | 2022-02-07 |
Family
ID=70328324
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021523258A Pending JP2022512847A (ja) | 2018-10-29 | 2019-10-28 | 操作されたdnaポリメラーゼバリアント |
JP2024025611A Pending JP2024057009A (ja) | 2018-10-29 | 2024-02-22 | 操作されたdnaポリメラーゼバリアント |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024025611A Pending JP2024057009A (ja) | 2018-10-29 | 2024-02-22 | 操作されたdnaポリメラーゼバリアント |
Country Status (12)
Country | Link |
---|---|
US (3) | US11060075B2 (ja) |
EP (1) | EP3874033A4 (ja) |
JP (2) | JP2022512847A (ja) |
KR (1) | KR20210084590A (ja) |
CN (1) | CN113316635A (ja) |
AU (1) | AU2019373208A1 (ja) |
BR (1) | BR112021008186A2 (ja) |
CA (1) | CA3116590A1 (ja) |
IL (1) | IL282456A (ja) |
MX (1) | MX2021004925A (ja) |
SG (1) | SG11202103639SA (ja) |
WO (1) | WO2020092216A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022512847A (ja) | 2018-10-29 | 2022-02-07 | コデクシス, インコーポレイテッド | 操作されたdnaポリメラーゼバリアント |
WO2024059581A2 (en) * | 2022-09-12 | 2024-03-21 | Codexis, Inc. | Engineered dna polymerase variants |
WO2024059547A2 (en) * | 2022-09-14 | 2024-03-21 | Codexis, Inc. | Engineered dna polymerase variants |
WO2024102861A2 (en) * | 2022-11-09 | 2024-05-16 | Codexis, Inc. | Dna polymerase variants |
WO2024138419A1 (zh) * | 2022-12-28 | 2024-07-04 | 深圳华大生命科学研究院 | 具有dna聚合酶活性的多肽及其应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001513983A (ja) * | 1997-08-29 | 2001-09-11 | ライフ テクノロジーズ,インコーポレイテッド | 高忠実度ポリメラーゼおよびその使用 |
JP2001269188A (ja) * | 2000-03-11 | 2001-10-02 | Roche Diagnostics Gmbh | Pcrにおける性能が向上したb型dnaポリメラーゼ変異体 |
JP2003519488A (ja) * | 2000-01-14 | 2003-06-24 | ユニバーシティ オブ ワシントン | 活性部位に1又は複数の変異を有するdnaポリメラーゼ変異体 |
JP2005514072A (ja) * | 2001-12-21 | 2005-05-19 | ストラタジーン カリフォルニア | 高忠実度dnaポリメラーゼ組成物およびその使用 |
JP2010104304A (ja) * | 2008-10-30 | 2010-05-13 | Hitachi Ltd | エキソヌクレアーゼ活性増強dnaポリメラーゼ変異体 |
WO2010144103A1 (en) * | 2009-06-11 | 2010-12-16 | Codexis, Inc. | Combined automated parallel synthesis of polynucleotide variants |
US8383346B2 (en) * | 2008-06-13 | 2013-02-26 | Codexis, Inc. | Combined automated parallel synthesis of polynucleotide variants |
JP2016536995A (ja) * | 2013-11-14 | 2016-12-01 | インテグレイテツド・デイー・エヌ・エイ・テクノロジーズ・インコーポレイテツド | 増大した鋳型識別活性を有するdnaポリメラーゼ突然変異体 |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US6309883B1 (en) | 1994-02-17 | 2001-10-30 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US6165793A (en) | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6406855B1 (en) | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US6395547B1 (en) | 1994-02-17 | 2002-05-28 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6995017B1 (en) | 1994-02-17 | 2006-02-07 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
US20060257890A1 (en) | 1996-05-20 | 2006-11-16 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5928905A (en) | 1995-04-18 | 1999-07-27 | Glaxo Group Limited | End-complementary polymerase reaction |
CN1192108C (zh) | 1994-06-03 | 2005-03-09 | 诺沃奇梅兹生物技术有限公司 | 纯化的毁丝霉属漆酶及编码该酶的核酸 |
EP0777737B1 (en) | 1994-06-30 | 2005-05-04 | Novozymes Biotech, Inc. | Non-toxic, non-toxigenic, non-pathogenic fusarium expression system and promoters and terminators for use therein |
FI104465B (fi) | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
US6096548A (en) | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
US6506602B1 (en) | 1996-03-25 | 2003-01-14 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
CZ293215B6 (cs) | 1996-08-06 | 2004-03-17 | F. Hoffmann-La Roche Ag | Rekombinantní tepelně stálá DNA polymeráza, způsob její přípravy a prostředek, který ji obsahuje |
US7148054B2 (en) | 1997-01-17 | 2006-12-12 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
AU6029998A (en) | 1997-01-17 | 1998-08-07 | Regents Of The University Of Minnesota | Dna molecules and protein displaying improved triazine compound degrading ability |
DE69835360T2 (de) | 1997-01-17 | 2007-08-16 | Maxygen, Inc., Redwood City | EVOLUTION Prokaryotischer GANZER ZELLEN DURCH REKURSIVE SEQUENZREKOMBINATION |
IL136574A0 (en) | 1997-12-08 | 2001-06-14 | California Inst Of Techn | A method for forming a polynucleotide of desired properties |
KR20010034731A (ko) | 1998-04-02 | 2001-04-25 | 텔루스 제너틱 리소시즈, 인크. | 유전자 서열 중에 유전자 병변이 있는 식물을 얻는 방법 |
CN1314911A (zh) | 1998-05-01 | 2001-09-26 | 麦克西根股份有限公司 | 用dna改组优化害虫抗性基因 |
AU4441699A (en) | 1998-06-17 | 2000-01-05 | Maxygen, Inc. | Method for producing polynucleotides with desired properties |
US6365408B1 (en) | 1998-06-19 | 2002-04-02 | Maxygen, Inc. | Methods of evolving a polynucleotides by mutagenesis and recombination |
US6605430B1 (en) | 1998-08-12 | 2003-08-12 | Maxygen, Inc. | DNA shuffling of monooxygenase genes for production of industrial chemicals |
WO2000020573A2 (en) | 1998-10-07 | 2000-04-13 | Maxygen, Inc. | Dna shuffling to produce nucleic acids for mycotoxin detoxification |
WO2000028018A1 (en) | 1998-11-10 | 2000-05-18 | Maxygen, Inc. | Modified adp-glucose pyrophosphorylase for improvement and optimization of plant phenotypes |
JP4221100B2 (ja) | 1999-01-13 | 2009-02-12 | エルピーダメモリ株式会社 | 半導体装置 |
US6376246B1 (en) | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US6917882B2 (en) | 1999-01-19 | 2005-07-12 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
US6368861B1 (en) | 1999-01-19 | 2002-04-09 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US6436675B1 (en) | 1999-09-28 | 2002-08-20 | Maxygen, Inc. | Use of codon-varied oligonucleotide synthesis for synthetic shuffling |
US7024312B1 (en) | 1999-01-19 | 2006-04-04 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
US8457903B1 (en) | 1999-01-19 | 2013-06-04 | Codexis Mayflower Holdings, Llc | Method and/or apparatus for determining codons |
US7873477B1 (en) | 2001-08-21 | 2011-01-18 | Codexis Mayflower Holdings, Llc | Method and system using systematically varied data libraries |
US7702464B1 (en) | 2001-08-21 | 2010-04-20 | Maxygen, Inc. | Method and apparatus for codon determining |
US20070065838A1 (en) | 1999-01-19 | 2007-03-22 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
EP1130093A1 (en) | 1999-01-19 | 2001-09-05 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US6961664B2 (en) | 1999-01-19 | 2005-11-01 | Maxygen | Methods of populating data structures for use in evolutionary simulations |
IL144657A0 (en) | 1999-02-11 | 2002-06-30 | Maxygen Inc | High throughput mass spectrometry |
US6531316B1 (en) * | 1999-03-05 | 2003-03-11 | Maxyag, Inc. | Encryption of traits using split gene sequences and engineered genetic elements |
EP1165775A2 (en) | 1999-03-05 | 2002-01-02 | Maxygen, Inc. | Recombination of insertion modified nucleic acids |
US6703240B1 (en) | 1999-04-13 | 2004-03-09 | Maxygar, Inc. | Modified starch metabolism enzymes and encoding genes for improvement and optimization of plant phenotypes |
US7430477B2 (en) | 1999-10-12 | 2008-09-30 | Maxygen, Inc. | Methods of populating data structures for use in evolutionary simulations |
US6519065B1 (en) | 1999-11-05 | 2003-02-11 | Jds Fitel Inc. | Chromatic dispersion compensation device |
US6686515B1 (en) | 1999-11-23 | 2004-02-03 | Maxygen, Inc. | Homologous recombination in plants |
JP2003519495A (ja) * | 2000-01-11 | 2003-06-24 | マキシジェン, インコーポレイテッド | 多様性生成およびスクリーニングのための一体化されたシステムおよび方法 |
WO2001075767A2 (en) | 2000-03-30 | 2001-10-11 | Maxygen, Inc. | In silico cross-over site selection |
DE60144145D1 (de) | 2000-04-03 | 2011-04-14 | Maxygen Inc | Subtilisin-variante |
CN1345937A (zh) * | 2000-09-29 | 2002-04-24 | 上海博德基因开发有限公司 | 一种新的多肽——人rna聚合酶ⅲ亚单位12.76和编码这种多肽的多核苷酸 |
US20050084907A1 (en) | 2002-03-01 | 2005-04-21 | Maxygen, Inc. | Methods, systems, and software for identifying functional biomolecules |
EP2315145B1 (en) | 2002-03-01 | 2015-11-25 | Codexis Mayflower Holdings, LLC | Methods, systems, and software for identifying functional biomolecules |
US7747391B2 (en) | 2002-03-01 | 2010-06-29 | Maxygen, Inc. | Methods, systems, and software for identifying functional biomolecules |
EP1488335A4 (en) | 2002-03-09 | 2006-11-15 | Maxygen Inc | OPTIMIZING CROSSOVER POINTS FOR THE ADJUSTED EVOLUTION |
EP1654354A1 (en) | 2003-08-11 | 2006-05-10 | Codexis, Inc. | Improved ketoreductase polypeptides and related polynucleotides |
EP1963536B1 (en) * | 2005-12-22 | 2016-05-04 | Pacific Biosciences of California, Inc. | Polymerases for nucleotide analogue incorporation |
WO2009102901A1 (en) | 2008-02-12 | 2009-08-20 | Codexis, Inc. | Method of generating an optimized, diverse population of variants |
US8504498B2 (en) | 2008-02-12 | 2013-08-06 | Codexis, Inc. | Method of generating an optimized, diverse population of variants |
DK3023494T3 (en) | 2008-06-13 | 2019-02-25 | Codexis Inc | PROCEDURE FOR SYNTHESIS OF POLYNUCLEOTIDE VARIETIES |
CA2742594C (en) * | 2008-11-03 | 2020-03-24 | William Bourn | Modified type a dna polymerases |
US20110082055A1 (en) * | 2009-09-18 | 2011-04-07 | Codexis, Inc. | Reduced codon mutagenesis |
DK2726651T3 (en) | 2011-06-28 | 2019-01-28 | Codexis Inc | PROTEIN INVARIANT GENERATION BY REGION SHUFFLING |
US20150133698A1 (en) | 2012-04-20 | 2015-05-14 | Codexis, Inc. | Production of fatty alcohols from engineered microorganisms |
FI2951754T3 (fi) | 2013-01-31 | 2024-05-16 | Codexis Inc | Menetelmät, järjestelmät ja ohjelmisto biomolekyylien tunnistamiseksi vuorovaikuttavien komponenttien avulla |
HUE055899T2 (hu) * | 2013-04-18 | 2022-01-28 | Codexis Inc | Átszerkesztett fenilalanin-ammónia-liáz polipeptidek |
EP3049973B1 (en) | 2013-09-27 | 2018-08-08 | Codexis, Inc. | Automated screening of enzyme variants |
BR112016006284B1 (pt) | 2013-09-27 | 2022-07-26 | Codexis, Inc | Método implementado por computador, produto de programa de computador, e, sistema de computador |
WO2015085230A1 (en) * | 2013-12-06 | 2015-06-11 | Bio-Rad Laboratories, Inc. | Fusion polymerases |
CN106701896A (zh) * | 2015-08-28 | 2017-05-24 | 王金 | 一种检测dna聚合酶保真度的方法 |
EP3192806A1 (en) | 2016-01-13 | 2017-07-19 | Affiris AG | Alpha chain of the high-affinity ige receptor (fceria) |
EP3402880B1 (en) * | 2016-01-15 | 2024-01-03 | Thermo Fisher Scientific Baltics UAB | Thermophilic dna polymerase mutants |
JP2022512847A (ja) | 2018-10-29 | 2022-02-07 | コデクシス, インコーポレイテッド | 操作されたdnaポリメラーゼバリアント |
-
2019
- 2019-10-28 JP JP2021523258A patent/JP2022512847A/ja active Pending
- 2019-10-28 CA CA3116590A patent/CA3116590A1/en active Pending
- 2019-10-28 KR KR1020217016433A patent/KR20210084590A/ko unknown
- 2019-10-28 SG SG11202103639SA patent/SG11202103639SA/en unknown
- 2019-10-28 MX MX2021004925A patent/MX2021004925A/es unknown
- 2019-10-28 AU AU2019373208A patent/AU2019373208A1/en active Pending
- 2019-10-28 US US16/666,280 patent/US11060075B2/en active Active
- 2019-10-28 BR BR112021008186-0A patent/BR112021008186A2/pt unknown
- 2019-10-28 WO PCT/US2019/058310 patent/WO2020092216A1/en unknown
- 2019-10-28 EP EP19878926.5A patent/EP3874033A4/en active Pending
- 2019-10-28 CN CN201980087146.5A patent/CN113316635A/zh active Pending
-
2021
- 2021-04-20 IL IL282456A patent/IL282456A/en unknown
- 2021-06-11 US US17/345,404 patent/US12018295B2/en active Active
-
2024
- 2024-02-22 JP JP2024025611A patent/JP2024057009A/ja active Pending
- 2024-04-05 US US18/628,461 patent/US20240263154A1/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001513983A (ja) * | 1997-08-29 | 2001-09-11 | ライフ テクノロジーズ,インコーポレイテッド | 高忠実度ポリメラーゼおよびその使用 |
JP2003519488A (ja) * | 2000-01-14 | 2003-06-24 | ユニバーシティ オブ ワシントン | 活性部位に1又は複数の変異を有するdnaポリメラーゼ変異体 |
JP2001269188A (ja) * | 2000-03-11 | 2001-10-02 | Roche Diagnostics Gmbh | Pcrにおける性能が向上したb型dnaポリメラーゼ変異体 |
JP2005514072A (ja) * | 2001-12-21 | 2005-05-19 | ストラタジーン カリフォルニア | 高忠実度dnaポリメラーゼ組成物およびその使用 |
US8383346B2 (en) * | 2008-06-13 | 2013-02-26 | Codexis, Inc. | Combined automated parallel synthesis of polynucleotide variants |
JP2010104304A (ja) * | 2008-10-30 | 2010-05-13 | Hitachi Ltd | エキソヌクレアーゼ活性増強dnaポリメラーゼ変異体 |
WO2010144103A1 (en) * | 2009-06-11 | 2010-12-16 | Codexis, Inc. | Combined automated parallel synthesis of polynucleotide variants |
JP2016536995A (ja) * | 2013-11-14 | 2016-12-01 | インテグレイテツド・デイー・エヌ・エイ・テクノロジーズ・インコーポレイテツド | 増大した鋳型識別活性を有するdnaポリメラーゼ突然変異体 |
Non-Patent Citations (1)
Title |
---|
"DNA polymerase [Thermococcus sp.2319x1]", NCBI PROTEIN DB [ONLINE], JPN6023034452, 6 January 2016 (2016-01-06), ISSN: 0005133393 * |
Also Published As
Publication number | Publication date |
---|---|
KR20210084590A (ko) | 2021-07-07 |
US12018295B2 (en) | 2024-06-25 |
WO2020092216A1 (en) | 2020-05-07 |
US20240263154A1 (en) | 2024-08-08 |
CA3116590A1 (en) | 2020-05-07 |
JP2024057009A (ja) | 2024-04-23 |
EP3874033A1 (en) | 2021-09-08 |
SG11202103639SA (en) | 2021-05-28 |
CN113316635A (zh) | 2021-08-27 |
US20210309977A1 (en) | 2021-10-07 |
MX2021004925A (es) | 2021-06-15 |
US11060075B2 (en) | 2021-07-13 |
US20200131485A1 (en) | 2020-04-30 |
EP3874033A4 (en) | 2022-08-03 |
AU2019373208A1 (en) | 2021-05-13 |
BR112021008186A2 (pt) | 2021-08-17 |
IL282456A (en) | 2021-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7401902B2 (ja) | 遺伝子操作されたリガーゼバリアント | |
JP2022512847A (ja) | 操作されたdnaポリメラーゼバリアント | |
US10883091B2 (en) | DNA polymerase variant and application thereof | |
JP2023159437A (ja) | T7 rnaポリメラーゼバリアント | |
JP2020530267A (ja) | T7 rnaポリメラーゼバリアント | |
CN114561374A (zh) | 一种新型嗜热核酸内切酶突变体及其制备方法和应用 | |
RU2820531C2 (ru) | Сконструированные варианты днк-полимеразы | |
CN118103500A (zh) | 重组逆转录酶变体 | |
US20230193224A1 (en) | Engineered dna polymerase variants | |
WO2024059547A2 (en) | Engineered dna polymerase variants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221024 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230822 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231121 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240119 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240510 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240809 |